Saint-Jerome, Canada Clinical Trials

A listing of Saint-Jerome, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Featured trial
Sickle Cell Disease Study: Own Your Health, Share Your Story with PicnicHealth

Get all of your medical records in one secure account and contribute to important real-world Sickle Cell research with PicnicHealth. If you have Sickle Cell, you get $50 for signing up and a free lifetime access to your medical records.   Visit this link to learn more and sign up. …

Online studies
PicnicHealth
(online study) Contact site
  • 11 views
  • 04 Aug, 2022
  • 1 location
  • Online study
Featured trial
Caregiver-Provided Life Review for Persons with Dementia

This study, Caregiver-Provided Life Review (C-PLR) is created based on Life Review therapy. It is for persons living with early-stage dementia along with mild depressive symptoms who are 65 years or older, community-dwellers or the residents of senior housing, independent or assisted living facilities conducted by their family members (18 …

depression
Online studies
dementia
Accepts healthy volunteers
Online Study Center
(online study) Contact site
  • 547 views
  • 09 Aug, 2022
  • 1 location
  • Online study
Objective, Passive Assessment of LRRK2 Carriers (OPAL)

This study is currently only open to active participants in the University of Rochester’s VALOR-PD study. The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless …

Online studies
movement disorder
University of Rochester
(online study) Contact site
  • 8 views
  • 12 May, 2022
  • 1 location
  • Online study
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Mcgill University Health center
 (27.5 away) Contact site
  • 4 views
  • 25 Jul, 2022
  • +508 other locations
Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303

NODE-303 is a multi-center, open label (OL) study to evaluate the safety of etripamil NS in patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients will be provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS will be self-applied by the patient, when PSVT symptoms begin. …

2003
 (0.7 away) Contact site
  • 116 views
  • 29 Jul, 2022
  • +80 other locations
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.

epidermal growth factor receptor
lung carcinoma
cancer
stage iv non-small cell lung cancer
measurable disease
Centre Integre de Sante et de Services Sociaux des Laurentides Hopital regional de Saint-Jerome
 (0.7 away) Contact site
  • 77 views
  • 06 May, 2022
  • +69 other locations
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it works to treat AD and what the side effects are when compared with a placebo …

eczema
topical agents
LEO Pharma Investigational Site
 (0.6 away) Contact site
  • 0 views
  • 03 Jul, 2022
  • +37 other locations
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation …

arterial disease
infarct
percutaneous coronary intervention
acute coronary syndrome
stemi
1240081 - Saint Jerome Medical Research, Inc.
 (0.7 away) Contact site
  • 1233 views
  • 27 Jul, 2022
  • +1635 other locations
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1)

The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.

antihypertensive drugs
hypertension
systolic blood pressure
Clinical Trial Site
 (9.4 away) Contact site
  • 40 views
  • 26 Jul, 2022
  • +68 other locations
A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis (AD-VISE)

Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns and outcomes with upadacitinib in a real-world setting. Therefore, the purpose of this observational …

inflammatory dermatosis
eczema
upadacitinib
Dre Angelique Gagne-Henley M.D. inc. /ID# 239604
 (0.6 away) Contact site
  • 8 views
  • 25 Jul, 2022
  • +43 other locations